The role of opioid receptors in modulating Alzheimer's Disease.

TitleThe role of opioid receptors in modulating Alzheimer's Disease.
Publication TypeJournal Article
Year of Publication2023
AuthorsTanguturi P, Streicher JM
JournalFront Pharmacol
Volume14
Pagination1056402
Date Published2023
ISSN1663-9812
Abstract

Alzheimer's disease (AD) is a complex neurological disorder characterized by accumulation of amyloid plaques and neurofibrillary tangles. Long term investigation of AD pathogenesis suggests that β-site amyloid precursor protein [APP] cleaving enzyme 1 (BACE1) and γ-secretase enzymes promote the amyloidogenic pathway and produce toxic Aβ peptides that are predisposed to aggregate in the brain. Hence, the targeted inhibition of BACE1/γ-secretase expression and function is a promising approach for AD therapy. Several reports have suggested that the opioid family of G-protein coupled receptors modulate the etiology of AD progression. It has also been found that changes in the signaling pathways of opioid receptors increased the expression of BACE1 and γ-secretase, and is strongly correlated with abnormal production of Aβ and pathogenesis of AD. Thus, the opioid receptor family is a promising candidate for targeted drug development to treat AD. In this review, we outline the involvement and mechanisms of opioid receptor signaling modulation in Alzheimer's Disease progression.

DOI10.3389/fphar.2023.1056402
Alternate JournalFront Pharmacol
PubMed ID36937877
PubMed Central IDPMC10014470
Grant ListR01 DA038635 / DA / NIDA NIH HHS / United States
Faculty Member Reference: 
John M. Streicher, PhD